A prodrug form of remogliflozin A
Related Products
Active Metabolite(s)
14340Remogliflozin A
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Remogliflozin etabonate

Item No. 14341

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, β-D-glucopyranoside 6-(ethyl carbonate)
CAS Number
442201-24-3
Synonyms
  • GSK189075
Molecular Formula
C26H38N2O9
Formula Weight
522.6
Purity
≥95%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: SolubleMethanol: Soluble
SMILES
CC(C)OC1=CC=C(CC2=C(C)N(C(C)C)N=C2O[C@@H]3O[C@H](COC(OCC)=O)[C@@H](O)[C@H](O)[C@H]3O)C=C1
InChi Code
InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
InChi Key
UAOCLDQAQNNEAX-ABMICEGHSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $134

    Add

    5 mg

    $598

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Remogliflozin etabonate is a prodrug form of the sodium-glucose transporter 2 (SGLT2) inhibitor remogliflozin A (Item No. 14340).1 Remogliflozin etabonate inhibits human SGLT2 and SGLT1 (Kis = 1.95 and 43.1 μM, respectively). It inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104) when administered at doses of 3 and 10 mg/ml. Remogliflozin etabonate (10 and 30 mg/kg twice per day for 6 weeks) also increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a db/db mouse model of diabetes with hyperinsulinemia and obesity.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fujimori, Y., Katsuno, K., Nakashima, I., et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 327(1), 268-276 (2008).